Desmopressin vs behaviour modifications
Major adverse events
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
62 questions · 64 findings · 30 reviews
No studies found 12 · 18.8%GRADE not reported 0 · 0%Very low 26 · 40.6%Low 11 · 17.2%Moderate 15 · 23.4%High 0 · 0%
Omega‐3 vs placebo
Serious adverse events: major bleeding · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: major bleeding compared with placebo (very low certainty).
1 finding from 1 review
- Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease 2018 · Cochrane Headline outcomes onlyRD 0.083 studies · 65 participantsVery low
Omega‐3 vs placebo
Serious adverse events: major bleeding · Dialysis vascular access outcomes in AVF patients with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
- Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Intervention not reported
Major adverse cardiovascular events (MACE) · people with intermittent claudication
The intervention showed no clear difference in major adverse cardiovascular events (MACE) (low certainty).
1 finding from 1 review
- Mobile health technologies to improve walking distance in people with intermittent claudication 2024 · Cochrane Headline outcomes onlyRR 1.37 [0.07, 28.17]1 study · 305 participantsLow
Intervention not reported
Major adverse cardiovascular events (MACE) · people with cardiovascular disease or at high risk of cardiovascular disease
The intervention probably leads to lower major adverse cardiovascular events (MACE) (moderate certainty).
1 finding from 1 review
- Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events 2018 · Cochrane Headline outcomes onlyRR 0.94 [0.9, 0.98]10 studies · 21727 participantsModerate
Quinine vs a quinine‐vitamin E combination (Q‐Vel)
Major adverse events · patients with muscle cramps
1 finding from 1 review
- no estimate extracted3 studies · 510 participantsModerate
Quinine vs placebo
Major adverse events · patients with muscle cramps
1 finding from 1 review
- no estimate extracted18 studies · 1103 participantsModerate
Quinine vs vitamin E
Major adverse events · patients with muscle cramps
1 finding from 1 review
- no estimate extracted3 studies · 513 participantsModerate
Antiplatelet therapy vs placebo
Any adverse events (excluding major bleeding) · people with cerebral small vessel disease and no dementia
1 finding from 1 review
- Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 50 participantsVery low
Dual antiplatelet therapy vs one antiplatelet agent
Any adverse events (excluding major bleeding) · people with cerebral small vessel disease and no dementia
The review found no eligible studies for this question.
1 finding from 1 review
- Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Antiplatelet drug vs placebo
Any adverse events (excluding major bleeding) · s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral…
1 finding from 1 review
- Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without… 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 280 participantsVery low
Higher polyunsaturated fatty acid (PUFA) vs lower PUFA
Major adverse cardiac and cerebrovascular events · people with or without existing CVD, men and women
It is very uncertain whether higher polyunsaturated fatty acid (PUFA) changes major adverse cardiac and cerebrovascular events compared with lower PUFA (very low certainty).
1 finding from 1 review
- Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease 2018 · Cochrane Headline outcomes onlyRR 0.84 [0.59, 1.2]2 studies · 2879 participantsVery low
Alpha‐blocker as adjuvant medical expulsive therapy plus usual care vs usual care
Major adverse events · adults with renal and ureteral stones undergoing shock wave lithotripsy
1 finding from 1 review
- Alpha‐blockers after shock wave lithotripsy for renal or ureteral stones in adults 2020 · Cochrane Headline outcomes onlyno estimate extracted7 studies · 747 participantsLow
Uterine artery embolization (UAE) vs surgery
Adverse events: major post‐procedural complications within one year · patients with symptomatic uterine fibroids
Uterine artery embolization (UAE) showed no clear difference in adverse events: major post‐procedural complications within one year compared with surgery (moderate certainty).
1 finding from 1 review
- OR 0.65 [0.33, 1.26]5 studies · 611 participantsModerate
Tobacco cessation interventions vs continuous smoking
MACE · patients with coronary heart disease
Smoking cessation may leads to lower major adverse cardiovascular events (MACE) at 19 months to 110 months compared with continuous smoking (low certainty).
1 finding from 1 review
- Smoking cessation for secondary prevention of cardiovascular disease 2022 · Cochrane Headline outcomes onlyHR 0.57 [0.45, 0.71]15 studies · 20521 participantsLow
Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs placebo
Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) · glabellar lines
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in major adverse events (eyelid ptosis, eyelid sensory disorder,… compared with placebo (moderate certainty).
1 finding from 1 review
- RR 3.36 [0.88, 12.87]7 studies · 1294 participantsModerate
Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs OnabotulinumtoxinA 20U
Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) · glabellar lines
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in major adverse events ‐ Any major adverse events (eyelid ptosis,… compared with onabotulinumtoxinA 20U (moderate certainty).
1 finding from 1 review
- OR 2.65 [0.77, 9.09]1 study · 433 participantsModerate
Intervention not reported
Adverse events (Re‐operation for bleeding (reoperation for major bleeding within 30 days (yes/no))) · adults undergoing surgery
It is very uncertain whether the intervention changes adverse events (Re‐operation for bleeding (reoperation for major… (very low certainty).
1 finding from 1 review
- Pre‐emptive and preventive NSAIDs for postoperative pain in adults undergoing all types of surgery 2021 · Cochrane Headline outcomes onlyRR 1.95 [0.18, 20.68]1 study · 81 participantsVery low
Summary of Findings Table ‐ Enoxaparin vs no enoxaparin
Adverse events: clinically relevant non‐major bleeding / heparin‐induced thrombocytopenia ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
- Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Corticosteroids vs placebo
Adverse events Assessed as: occurrence of one or more major adverse events requiring withdrawal of treatment · people with nerve damage (< 6 months' duration) in leprosy
Corticosteroids showed no clear difference in adverse events Assessed as: occurrence of one or more major adverse… compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.83 [0.05, 12.77]1 study · 75 participantsModerate